Global Cord Blood Corporation (CO) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CO - KYG393421030 - Common Stock
2.9876 USD
+0.77 (+34.58%)
2.925 USD
-0.06 (-2.1%)
Taking everything into account, CO scores 2 out of 10 in our fundamental rating. CO was compared to 103 industry peers in the Health Care Providers & Services industry. CO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year CO was profitable.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.87% | ||
| ROE | 10.27% | ||
| ROIC | 6.39% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.97% | ||
| PM (TTM) | 40.3% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CO is destroying value.
- CO has about the same amout of shares outstanding than it did 1 year ago.
- There is no outstanding debt for CO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- CO has an Altman-Z score of 2.21. This is not the best score and indicates that CO is in the grey zone with still only limited risk for bankruptcy at the moment.
- There is no outstanding debt for CO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.21 |
ROIC/WACC0.73
WACC8.75%
2.3 Liquidity
- A Current Ratio of 10.73 indicates that CO has no problem at all paying its short term obligations.
- A Quick Ratio of 10.66 indicates that CO has no problem at all paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.73 | ||
| Quick Ratio | 10.66 |
3. Growth
3.1 Past
- CO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.41%.
- Measured over the past 5 years, CO shows a small growth in Earnings Per Share. The EPS has been growing by 7.71% on average per year.
- CO shows a small growth in Revenue. In the last year, the Revenue has grown by 7.21%.
- The Revenue has been growing by 10.34% on average over the past years. This is quite good.
EPS 1Y (TTM)-1.41%
EPS 3Y8.03%
EPS 5Y7.71%
EPS Q2Q%-18%
Revenue 1Y (TTM)7.21%
Revenue growth 3Y8%
Revenue growth 5Y10.34%
Sales Q2Q%-1.69%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 5.15, which indicates a rather cheap valuation of CO.
- When comparing the Price/Earnings ratio of CO to the average of the S&P500 Index (27.21), we can say CO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.15 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -5.81 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.67
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- CO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Global Cord Blood Corporation / CO FAQ
What is the ChartMill fundamental rating of Global Cord Blood Corporation (CO) stock?
ChartMill assigns a fundamental rating of 6 / 10 to CO.
Can you provide the valuation status for Global Cord Blood Corporation?
ChartMill assigns a valuation rating of 9 / 10 to Global Cord Blood Corporation (CO). This can be considered as Undervalued.
Can you provide the profitability details for Global Cord Blood Corporation?
Global Cord Blood Corporation (CO) has a profitability rating of 5 / 10.
What is the valuation of Global Cord Blood Corporation based on its PE and PB ratios?
The Price/Earnings (PE) ratio for Global Cord Blood Corporation (CO) is 5.15 and the Price/Book (PB) ratio is 0.58.